The global Pruritus Therapeutics market size is expected to reach USD 13.2 Billion by 2032, exhibiting the CAGR of 3.8% during the forecast period.
The Pruritus Therapeutics Market has garnered significant attention in recent years as pruritus, or chronic itching, remains one of the most common and distressing symptoms of numerous dermatological and systemic diseases. The market is growing rapidly as the demand for effective treatments increases due to the wide-ranging causes of pruritus, which includes skin conditions like eczema, psoriasis, and allergic reactions, as well as internal disorders like liver disease and kidney failure.
Key Market Trends
- Development of Biologic Treatments
Biologics like dupilumab (Dupixent) and other monoclonal antibodies are revolutionizing the treatment of pruritus in conditions like atopic dermatitis and psoriasis. These biologics are gaining popularity due to their efficacy in treating both pruritus and the underlying inflammation. - Rise in Non-Steroidal Treatments
There is a growing demand for non-steroidal therapies for pruritus, as long-term use of corticosteroids can have adverse side effects, such as skin thinning. Non-steroidal treatments like JAK inhibitors and neurokinin-1 receptor antagonists are becoming increasingly important in managing chronic pruritus, particularly in systemic conditions. - Combination Therapies
Combination treatments, involving topical, systemic, and alternative therapies, are becoming a key trend. By addressing multiple pathways involved in pruritus, combination therapies offer better control over symptoms and reduce the chances of resistance to single-drug therapies.
Download Free Sample PDF Copy of the Report:
Some of the major players operating in the global market include:
- AbbVie Inc.
- Amgen Inc.
- Astellas Pharma Inc.
- Bristol Myers Squibb
- Cara Therapeutics
- GSK plc
- Novartis AG
- Pfizer Inc.
Challenges in the Pruritus Therapeutics Market
- Side Effects of Current Treatments
Many existing treatments, especially corticosteroids, have side effects such as skin thinning, which can limit long-term use. Patients may also experience treatment resistance, leading to the need for more effective alternatives. - Lack of Awareness in Developing Regions
While awareness of pruritus is rising globally, many developing regions still lack sufficient resources for diagnosis and treatment. This limits the reach of therapeutic options and hinders early intervention. - Expensive Biologic Treatments
Biologic therapies, while highly effective, are expensive and not always covered by insurance, creating access issues for many patients, particularly in low-income regions.
𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐥 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰:
The research report categorizes the market into various segments and sub-segments. The primary segments covered in the study include type, application, end use and region. The splitting of the market into various groups enables businesses to understand market preferences and trends better. Also, stakeholders can develop products/services that align with the diverse needs of consumers in the industry. Besides, the research study includes a thorough examination of all the major sub-segments in the market.
Pruritus Therapeutics, Disease Type Outlook
- Allergic Contact Dermatitis
- Atopic Dermatitis
- Urticaria
- Othersc
Pruritus Therapeutics, Product Outlook
- Antihistamines
- Calcineurin Inhibitors
- Corticosteroids
- Counterirritants
- Immunosuppressant
- Local Anesthetics
- Others
Recent Developments
- In September 2023, Cara Therapeutics, Inc., a company specializing in biopharmaceuticals, announced that its licensing partner, Maruishi Pharmaceutical Co., Ltd., has received approval from Japan’s Ministry of Health, Labour and Welfare for the manufacturing and marketing of KORSUVA IV Injection Syringe. This approval is for the treatment of pruritus in hemodialysis patients, marking a significant advancement in addressing this condition.
- In February 2024, Galderma has announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Applications for nemolizumab. This application is for the treatment of prurigo nodularis and adolescents and adults with moderate to severe atopic dermatitis.
- In November 2020, Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company focused on developing assets to regulate immunological pathways for various diseases, has announced that the U.S. Food and Drug Administration (FDA) has granted vixarelimab Breakthrough Therapy designation for treating pruritus associated with prurigo nodularis.
The Pruritus Therapeutics Market is experiencing rapid growth as new and more effective therapies for chronic itching are developed. With an increasing understanding of the pathophysiology of pruritus, the market is evolving towards more targeted and personalized treatment options. Although challenges such as treatment costs and